Presentation by BSB Group Leaders Kevin Saliba and Naresh Verma

Description

This presentation will be a session of Group Leader talks (two seminars, each 25 minutes). The speakers and their respective topics are:

Naresh Verma: Vaccine design against shigellosis: are we there yet?

Bacillary dysentery or shigellosis is caused by bacteria belong to the genus Shigella. S. flexneri is the predominant species in endemic areas and the principal cause of morbidity and mortality in children under five years of age in developing countries. A variety of approaches have been used but no effective vaccine is available for prevention of shigellosis at present. This talk will review the strategies used for Shigella vaccine development to date and present our recent work on the development of both live attenuated and subunit vaccines to achieve a broad-spectrum protection against shigellosis including the newly identified serotypes of S. flexneri. Furthermore, identification of novel antigenic proteins using a proteomic approach, and their role in pathogenesis and potential in vaccine development will also be discussed.

Read more about Naresh Verma.

Kevin Saliba: The coenzyme A biosynthesis pathway of the human malaria parasite and its potential as a drug target

Read more about Kevin Saliba.

Sandwiches (including vegetarian and vegan) and juice will be provided.

Date & time

1–2pm 17 July 2014

Location

Slatyer Seminar Room,
R.N. Robinson Building (Bldg 46),
Cunningham Close, ANU

Speakers

Kevin Saliba

Contacts

 Graham Hicks
 +61 2 612 52655

Updated:  17 December 2017/Responsible Officer:  Director RSB/Page Contact:  Webmaster RSB